Clinical Trial Detail

NCT ID NCT02454179
Title Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Head and Neck Squamous Cell Carcinoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Acerta Pharma BV
Indications

head and neck squamous cell carcinoma

oropharynx cancer

laryngeal squamous cell carcinoma

hypopharynx cancer

oral squamous cell carcinoma

Therapies

Pembrolizumab

Acalabrutinib

Age Groups: adult

No variant requirements are available.